Cenovus Energy Inc
Change company Symbol lookup
Select an option...
CVE Cenovus Energy Inc
DIDIY DiDi Global Inc
PPBT Purple Biotech Ltd
PRE Prenetics Global Ltd
APTV Aptiv PLC
$NQUSB60101015LMCAD Nasdaq US Offshore Drilling and Othe
CUTR Cutera Inc
FRD Friedman Industries Inc
PRPRF Prairie Provident Resources Inc
BAC Bank of America Corp
Go

Energy : Oil, Gas & Consumable Fuels | Large Cap Value
Based in Canada
Company profile

Cenovus Energy Inc. is a Canada-based integrated energy company, which is engaged in producing, refining and upgrading crude oil and natural gas, with operations in Canada, the United States and the Asia Pacific region. The Company's segments include Upstream, Downstream, and Corporate and Eliminations. The Upstream segment includes Oil Sands, Conventional, Heavy Oil and Offshore. The Downstream Segment includes Canadian Manufacturing, United States Manufacturing, and Retail. The Company's upstream operations include oil sands projects in northern Alberta, thermal and conventional crude oil, natural gas and natural gas liquids (NGLs) projects across Western Canada, crude oil production offshore Newfoundland and Labrador and natural gas and NGLs production offshore China and Indonesia. Its downstream operations include upgrading, refining and retail operations in Canada and the United States.

Premarket

Last Trade
Delayed
$15.21
-0.24 (-1.55%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$15.45
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
13,401

10-day average volume:
6,731,738
13,401

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 8, 2022

4:28 pm ET July 28, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NasdaqGM:CRVS), EQNX::TICKER_END Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on August 8, 2022 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2022 financial results.

The conference call can be accessed by 1-844-825-9789 (toll-free domestic) or 1-412-317-5180 (international) and using the conference ID 10169996. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is mupadolimab (CPI-006), a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical and clinical studies. The Company's second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:

Leiv Lea

Chief Financial Officer

Corvus Pharmaceuticals, Inc.

+1-650-900-4522

llea@corvuspharma.com

MEDIA CONTACT:

Sheryl Seapy

Real Chemistry

+1-949-903-4750

sseapy@realchemistry.com

https://ml.globenewswire.com/media/70c77c96-f27f-4032-aa6c-454977cdd6a2/small/corvus-logo-small-jpg.jpg

https://ml.globenewswire.com/media/70c77c96-f27f-4032-aa6c-454977cdd6a2/small/corvus-logo-small-jpg.jpg

comtex tracking

COMTEX_411183678/2010/2022-07-28T16:28:35

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.